Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Conditions
- Acute Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Graft Versus Host Disease
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Myelodysplastic Syndrome
- Myelofibrosis
- Myeloproliferative Neoplasm
- Small Lymphocytic Lymphoma
Interventions
- BIOLOGICAL: Thymoglobulin
- DRUG: Bortezomib
- DRUG: Tacrolimus
Sponsor
Emory University